Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867
|
CN |
|
Z
|
ZeusCo Ltd
KOSDAQ:079370
|
KR |
|
Camtek Ltd
F:CMZ
|
IL |
|
C
|
China Regenerative Medicine International Ltd
HKEX:8158
|
HK |
|
Air Canada
TSX:AC
|
CA |
|
Perfect Medical Health Management Ltd
HKEX:1830
|
HK |
|
C
|
Castellum Inc
AMEX:CTM
|
US |
|
Radico Khaitan Ltd
NSE:RADICO
|
IN |
|
MIT Holdings Co Ltd
TSE:4016
|
JP |
|
T
|
Tantalus Systems Holding Inc
TSX:GRID
|
CA |
|
Bank of N T Butterfield & Son Ltd
NYSE:NTB
|
BM |
|
I
|
IPS Inc
TSE:4390
|
JP |
|
Portobello SpA
MIL:POR
|
IT |
|
H
|
Healius Ltd
ASX:HLS
|
AU |
|
C
|
CIE Automotive SA
MAD:CIE
|
ES |
|
PT Bank Neo Commerce Tbk
IDX:BBYB
|
ID |
|
Suryamas Dutamakmur Tbk PT
IDX:SMDM
|
ID |
Wall Street
Price Targets
Price Targets Summary
Tonghua Dongbao Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for Tonghua Dongbao Pharmaceutical Co Ltd is 11.19 CNY with a low forecast of 8.08 CNY and a high forecast of 14.7 CNY.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Tonghua Dongbao Pharmaceutical Co Ltd's stock price target?
Price Target
11.19
CNY
According to Wall Street analysts, the average 1-year price target for Tonghua Dongbao Pharmaceutical Co Ltd is 11.19 CNY with a low forecast of 8.08 CNY and a high forecast of 14.7 CNY.
What is Tonghua Dongbao Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
22%
For the last 13 years the compound annual growth rate for Tonghua Dongbao Pharmaceutical Co Ltd's revenue is 8%. The projected CAGR for the next 3 years is 22%.
What is Tonghua Dongbao Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
104%
For the last 13 years the compound annual growth rate for Tonghua Dongbao Pharmaceutical Co Ltd's operating income is 11%. The projected CAGR for the next 3 years is 104%.
